- Open
- 1.23
- High
- 1.25
- Low
- 1.17
- Close
- 1.22
- Change
- -0.13 (-10.20%)
- Volume
- 3,812,414
⌘K
| 5 Jun 2026 | 07:00:03 | Receipt of R&D tax credit |
| 1 Jun 2026 | 07:00:11 | Block Listing Returns |
| 26 May 2026 | 07:00:15 | Board Changes |
| 6 May 2026 | 11:56:49 | Holding(s) in Company |
| 5 May 2026 | 07:00:13 | Sussex NHS Trust transitions MT-RNR1 test to BAU |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
genedrive plc is a company that specializes in molecular diagnostics. They are focused on creating a point-of-need platform that is affordable, fast, flexible, user-friendly, and reliable. This platform is designed to diagnose infectious diseases, as well as to help with patient stratification, pathogen detection, and other medical needs.
| 5 Jun 2026 | 07:00:03 | Receipt of R&D tax credit |
| 1 Jun 2026 | 07:00:11 | Block Listing Returns |
| 26 May 2026 | 07:00:15 | Board Changes |
| 6 May 2026 | 11:56:49 | Holding(s) in Company |
| 5 May 2026 | 07:00:13 | Sussex NHS Trust transitions MT-RNR1 test to BAU |
| 22 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 23 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 2 Jan 2024 | Annual Report and Accounts (to 2023-06-30) |
genedrive plc is a company that specializes in molecular diagnostics. They are focused on creating a point-of-need platform that is affordable, fast, flexible, user-friendly, and reliable. This platform is designed to diagnose infectious diseases, as well as to help with patient stratification, pathogen detection, and other medical needs.
| 28 Oct 2019 |
| Acceleration of news flow expected |
| 18 Jul 2019 | Hepatitis C market frustrations |
| 8 Apr 2019 | First commercial sales in new focus area: bio-threats |
| 10 Dec 2018 | Accelerating into fiscal 2019 with first sales |
| 28 Oct 2019 |
| Acceleration of news flow expected |
| 18 Jul 2019 | Hepatitis C market frustrations |
| 8 Apr 2019 | First commercial sales in new focus area: bio-threats |
| 10 Dec 2018 | Accelerating into fiscal 2019 with first sales |